Trials / Completed
CompletedNCT02234596
Nintedanib in Patients With Advanced Esophagogastric Cancer
Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity. |
Timeline
- Start date
- 2014-09-04
- Primary completion
- 2020-04-22
- Completion
- 2020-04-22
- First posted
- 2014-09-09
- Last updated
- 2021-01-25
- Results posted
- 2021-01-25
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02234596. Inclusion in this directory is not an endorsement.